[State of the art management of patients presenting an ischemia with non-obstructive coronary arteries (ANOCA/INOCA)]. / Prise en charge de l'angine de poitrine et/ou de l'ischémie sans maladie coronarienne obstructive (ANOCA/INOCA).

Angor with non-obstructive coronary arteries or ischemia with non-obstructive coronary arteries (ANOCA/INOCA) is a condition where a patient experiences symptoms and/or signs of myocardial ischemia, without significant coronary artery stenoses. This syndrome is often caused by a direct imbalance between supply and demand, leading to inadequate myocardial perfusion due to microvascular limitations or coronary arteries' spasms. Although previously considered benign, there is increasing evidence that ANOCA/INOCA is associated with a poor quality of life, significant burden on the healthcare system, and major adverse cardiac events. This article reviews the definition of ANOCA/INOCA, epidemiology, risk factors, management, and current knowledge gaps and clinical trials.

La maladie coronarienne se présente classiquement sous forme de sténoses au niveau des artères coronariennes épicardiques. Cependant, un grand nombre de patients présentent des douleurs thoraciques et/ou un test non invasif positif pour une ischémie sans sténose coronarienne significative à l'angiographie. Il s'agit d'une maladie coronarienne non obstructive nommée ANOCA ou INOCA (Angina with Non Obstructive Coronary Arteries ou Ischemia with Non Obstructive Coronary Arteries). La cause peut être une atteinte de la microcirculation coronarienne ou un spasme des artères épicardiques. Longtemps considérée comme bénigne, peu de recherches ont été consacrées à l'ANOCA/INOCA. Cependant, de plus en plus de données montrent un impact sur les événements cardiaques majeurs, la qualité de vie et les coûts du système de santé.

Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.

In these times of COVID-19 pandemic, concern has been raised about the potential effects of SARS-CoV-2 infection on immunocompromised patients, particularly on those receiving B-cell depleting agents and having therefore a severely depressed humoral response. Convalescent plasma can be a therapeutic option for these patients. Understanding the underlying mechanisms of convalescent plasma is crucial to optimize such therapeutic approach. Here, we describe a COVID-19 patient who was deeply immunosuppressed following rituximab (anti-CD20 monoclonal antibody) and concomitant chemotherapy for chronic lymphoid leukemia. His long-term severe T and B cell lymphopenia allowed to evaluate the treatment effects of convalescent plasma. Therapeutic outcome was monitored at the clinical, biological and radiological level. Moreover, anti-SARS-CoV-2 antibody titers (IgM, IgG and IgA) and neutralizing activity were assessed over time before and after plasma transfusions, alongside to SARS-CoV-2 RNA quantification and virus isolation from the upper respiratory tract. Already after the first cycle of plasma transfusion, the patient experienced rapid improvement of pneumonia, inflammation and blood cell counts, which may be related to the immunomodulatory properties of plasma. Subsequently, the cumulative increase in anti-SARS-CoV-2 neutralizing antibodies due to the three additional plasma transfusions was associated with progressive and finally complete viral clearance, resulting in full clinical recovery. In this case-report, administration of convalescent plasma revealed a stepwise effect with an initial and rapid anti-inflammatory activity followed by the progressive SARS-CoV-2 clearance. These data have potential implications for a more extended use of convalescent plasma and future monoclonal antibodies in the treatment of immunosuppressed COVID-19 patients.